Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
6(35%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
12%
Ph phase_1
4
24%
Ph not_applicable
2
12%
Ph phase_3
6
35%
Ph phase_4
2
12%

Phase Distribution

4

Early Stage

2

Mid Stage

8

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
4(25.0%)
Phase 2Efficacy & side effects
2(12.5%)
Phase 3Large-scale testing
6(37.5%)
Phase 4Post-market surveillance
2(12.5%)
N/ANon-phased studies
2(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

17

all time

Status Distribution
Active(9)
Completed(5)
Other(3)

Detailed Status

Recruiting5
Completed5
unknown3
Not yet recruiting2
Enrolling by invitation1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
6
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (25.0%)
Phase 22 (12.5%)
Phase 36 (37.5%)
Phase 42 (12.5%)
N/A2 (12.5%)

Trials by Status

enrolling_by_invitation16%
recruiting529%
completed529%
unknown318%
active_not_recruiting16%
not_yet_recruiting212%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT07349069Phase 3

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

Recruiting
NCT07389733Phase 1

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Not Yet Recruiting
NCT07024173Phase 3

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Recruiting
NCT04906395Phase 3

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Active Not Recruiting
NCT05645536Phase 3

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Enrolling By Invitation
NCT06974929Phase 1

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

Recruiting
NCT07168837Not Applicable

Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction

Completed
NCT06861803

Laboratory and Ultrasound Findings and Response to Letrozole in PCOS Patients

Not Yet Recruiting
NCT05847257Phase 2

Impact of Co Enzyme Q10 as Adjuvant Therapy to Letrozole on Spermiogram

Completed
NCT05601700Phase 3

Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

Recruiting
NCT06367712Phase 1

Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol

Completed
NCT06354439Phase 4

Use of Letrozole for Ectopic Pregnancy

Recruiting
NCT06047184Phase 1

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

Unknown
NCT05198050Not Applicable

Letrozole in Induction of Abortion of Anembryonic Pregnancy

Completed
NCT04341545Phase 3

Letrozole in Tubal Ectopic Pregnancy

Unknown
NCT05203562Phase 2

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

Unknown
NCT05198141Phase 4

Evaluation of Different Doses of Letrozole in Ectopic Pregnancy

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17